Table 1 Patient characteristics within the study population by subgroup
Parameter | All cases (n= 1,540) | All ER-positive (n= 1,189) | ER-positive tamoxifen onlya(n= 831) | ER-positive, node-negative, tamoxifen onlya(n= 657) |
|---|---|---|---|---|
Age | ||||
< 50 years | 660 (42.8%) | 505 (42.5%) | 284 (34.2%) | 243 (37.0%) |
> 50 years | 879 (57.1%) | 683 (57.4%) | 547 (65.8%) | 414 (63.0%) |
Missing | 1 (0.1%) | 1 (0.1%) | ||
Grade | ||||
1 | 411 (26.7%) | 359 (30.2%) | 269 (32.4%) | 215 (32.7%) |
2 | 710 (46.1%) | 581 (48.9%) | 416 (50.1%) | 323 (49.2%) |
3 | 381 (24.7%) | 233 (19.6%) | 135 (16.2%) | 109 (16.6%) |
Missing | 38 (2.5%) | 16 (1.3%) | 11 (1.3%) | 10 (1.5%) |
Nodes | ||||
Negative | 1164 (75.6%) | 889 (74.8%) | 657 (79.1%) | 657 (100%) |
1 to 3 | 321 (20.8%) | 264 (22.2%) | 154 (18.5%) | |
4 to 9 | 44 (2.9%) | 29 (2.4%) | 17 (2.0%) | |
10+ | 9 (0.6%) | 5 (0.4%) | 3 (0.4%) | |
Missing | 2 (0.1%) | 2 (0.2%) | ||
Size | ||||
< 20 mm | 1150 (74.7%) | 903 (75.9%) | 648 (78.0%) | 531 (80.8%) |
> 20 mm | 314 (20.4%) | 224 (18.8%) | 148 (17.8%) | 99 (15.1%) |
Missing | 76 (4.9%) | 62 (5.2%) | 35 (4.2%) | 27 (4.1%) |
Estrogen receptor | ||||
< 2 | 278 (18.1%) | 19 (1.6%) | 15 (1.8%) | 14 (2.1%) |
Allred 3 to 5 | 347 (22.5%) | 347 (29.2%) | 213 (25.6%) | 174 (26.5%) |
Allred 6 to 8 | 823 (53.4%) | 823 (69.2%) | 603 (72.6%) | 469 (71.4%) |
Missing | 92 (6.0%) | |||
Progesterone receptor | ||||
< 2 | 242 (15.7%) | 131 (11.0%) | 90 (10.8%) | 74 (11.3%) |
Allred 3 to 5 | 334 (21.7%) | 245 (20.6%) | 180 (21.6%) | 144 (21.9%) |
Allred 6 to 8 | 866 (56.2%) | 785 (66.0%) | 542 (65.2%) | 422 (64.2%) |
Missing | 98 (6.4%) | 28 (2.4%) | 19 (2.3%) | 17 (2.6%) |